Polianta Ltd Makes New Investment in Humana Inc. $HUM

Key Points

• Polianta Ltd invested approximately $1.30 million in Humana Inc. by purchasing 5,300 shares during the second quarter.
• The company has a market capitalization of $32.43 billion and reported earnings of $6.27 per share for the last quarter, missing the consensus estimate by $0.05.
• Humana recently announced a quarterly dividend of $0.885 per share, which is set to be paid to investors on October 31st, representing an annualized yield of 1.3%.

Polianta Ltd bought a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 5,300 shares of the insurance provider's stock, valued at approximately $1,295,000.

A number of other hedge funds also recently modified their holdings of the business. Mn Services Vermogensbeheer B.V. raised its position in shares of Humana by 1.1% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 45,012 shares of the insurance provider's stock worth $11,005,000 after purchasing an additional 500 shares during the period. Swedbank AB grew its stake in Humana by 5.3% in the second quarter. Swedbank AB now owns 100,397 shares of the insurance provider's stock valued at $24,545,000 after purchasing an additional 5,032 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Humana by 12.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 15,647 shares of the insurance provider's stock valued at $3,825,000 after purchasing an additional 1,692 shares in the last quarter. Sivia Capital Partners LLC grew its stake in Humana by 53.7% in the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider's stock valued at $316,000 after purchasing an additional 452 shares in the last quarter. Finally, Procyon Advisors LLC bought a new position in Humana in the second quarter valued at approximately $227,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

HUM traded down $12.47 on Friday, reaching $252.39. The stock had a trading volume of 4,954,304 shares, compared to its average volume of 1,678,064. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $324.38. The firm has a 50-day moving average of $268.56 and a 200-day moving average of $257.29. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $30.35 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.48 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter last year, the firm posted $6.96 EPS. The company's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. Humana's dividend payout ratio is 27.17%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Bank of America lifted their target price on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada lifted their target price on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. Barclays lifted their price target on Humana from $275.00 to $315.00 and gave the stock an "equal weight" rating in a report on Friday, September 5th. Robert W. Baird dropped their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a report on Friday, July 25th. Finally, Wall Street Zen cut Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Seven analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $289.24.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.